GH Form 4: Director now holds 7,841 shares after 250 RSUs settle

Rhea-AI Filing Summary

Guardant Health (GH) director reports Form 4 activity. On 10/15/2025, 250 shares of common stock were acquired at $0 following the settlement of restricted stock units (transaction code M). After this transaction, the reporting person directly owns 7,841 shares.

The related derivative line shows 250 restricted stock units converted into 250 shares at $0 on 10/15/2025, leaving 4,248 derivative securities (restricted stock units) directly beneficially owned after the event.

The award referenced in the footnotes was granted on March 6, 2023 and vests over four years: 25% vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting monthly over the following three years.

Insider Trade Summary

250 shares exercised/converted

Mixed 2 txns

Insider Tariq Musa

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	250	$0.00	--
Exercise	Common Stock	250	$0.00	--

Holdings After Transaction: Restricted Stock Units — 4,248 shares (Direct); Common Stock — 7,841 shares (Direct)

Footnotes (1)

1. The restricted stock unit award granted on March 6, 2023 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of March 15, 2023 and the remaining 75% vests monthly for the three-year period thereafter. Not applicable for Restricted Stock Units.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tariq Musa

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2025		M		250	A	$0	7,841	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	10/15/2025		M			250	(1)	(2)	Common Stock	250	$0	4,248	D

Explanation of Responses:

1. The restricted stock unit award granted on March 6, 2023 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of March 15, 2023 and the remaining 75% vests monthly for the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Musa Tariq	10/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Guardant Health (GH) disclose in this Form 4?

A director acquired 250 common shares on 10/15/2025 via RSU settlement (code M) at $0.

How many GH shares does the reporting person own after the transaction?

The filing shows 7,841 common shares directly owned after the transaction.

What derivative securities remain after this Form 4 event for GH?

The report lists 4,248 restricted stock units directly beneficially owned after the transaction.

What is the vesting schedule of the RSU award mentioned?

Granted on March 6, 2023, it vests over four years: 25% on the one-year anniversary of March 15, 2023, then monthly over the next three years.

What is the transaction code and price for the share acquisition?

Transaction code M (derivative conversion) and a per-share price of $0.

What is the reporting person’s relationship to Guardant Health?

The reporting person is a Director of Guardant Health, Inc.